Developer docs
API playgroundTry for free, no card

Search company profiles

Rose BioSolutions

Full company profile

uuid02bkh1w

Namestring
Rose BioSolutions
Legal namestring
Rose BioSolutions
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Rose BioSolutions is a privately held, PE-backed contract development and manufacturing organization focused on cell and gene therapy. It was formed in May 2026 when GI Partners acquired Charles River Laboratories' CDMO and Cell Solutions businesses. Headquartered in Memphis, Tennessee, Rose operates facilities in Memphis and Rockville, Maryland, and Keele, United Kingdom, with an indicated workforce of roughly 500 employees and 25 GMP suites.

Its service portfolio includes GMP plasmid manufacturing through eXpDNA, AAV vector production through nAAVigation, lentiviral vectors through Lentivation, cellular starting materials through Cell Solutions, and broader cell therapy CDMO services. Rose reports more than 30 years of viral-vector experience, more than 20 years of GMP manufacturing experience, regulatory approvals associated with the FDA, EMA, and MHRA, and 200 GMP-compliant products.

Rose serves more than 35 cell therapy clients. Named examples include AAVantgarde, a small biotechnology company, and the FOXG1 Research Foundation, a nonprofit organization. The business uses quote-based, project-based contracting, and the company is positioned to continue investing in infrastructure, capacity, and technical capabilities while a Charles River partnership for clinical testing continues.

Short descriptiontext

Rose BioSolutions is a privately held CDMO providing cell and gene therapy developers with GMP plasmid, viral-vector, cellular starting-material manufacturing, and related development services across U.S. and U.K. facilities through project-based contracts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMemphis, United States
HQ citystring
Memphis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, gene therapy CDMO, plasmid DNA production, viral vector manufacturing, biologics contract development
Industry5 codes
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell and Gene Therapy CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Manufacturing Services
TypeManaged Services
Description

Contract Development and Manufacturing Organization services including plasmid DNA manufacturing, viral vector manufacturing, and cell therapy manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies developing advanced therapies.

rosebiosolutions.com
2Cell and Biospecimen Products
TypeOne Time License
Description

Sale of human immune cells, stem cells, leukopaks, GMP-compliant cellular starting materials, and related biological products for research and clinical use.

rosebiosolutions.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1Custom CDMO service quotes based on project scope, phase, and grade requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing tailored to individual program requirements. Phase-appropriate grades available: Research Grade (RG), High Quality (HQ), and GMP.

rosebiosolutions.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1nAAVigation®
Description

Proprietary adeno-associated viral (AAV) vector production platform that reduces production timelines by over 60%

rosebiosolutions.com
+2 more records
Core offering1 text field

Rose BioSolutions is a Contract Development and Manufacturing Organization (CDMO) providing integrated cell and gene therapy manufacturing services across plasmid DNA, viral vectors, and cell therapy production. The company also supplies cellular starting materials (human immune cells, stem cells, leukopaks, and GMP-compliant biological products) for advanced therapy developers. Services span research-grade through GMP-grade production and include process development, analytical development, and regulatory support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 60% reduction in viral vector production timelines using proprietary platforms
+5 more records
Product overview1 text field

Rose BioSolutions offers an integrated portfolio of advanced therapy manufacturing services and cellular starting materials. The core offering centers on CDMO Solutions providing end-to-end Contract Development and Manufacturing Organization services across plasmid DNA manufacturing (via the eXpDNA platform), viral vector manufacturing (via nAAVigation and Lentivation platforms), and cell therapy CDMO services. Complementing these are Cell Solutions for sourcing human immune cells, stem cells, and GMP-compliant cellular starting materials. The company also provides specialized sub-products including off-the-shelf plasmid products, viral vector packaging services, CAR-T manufacturing support, and quality/regulatory services. This unified portfolio enables seamless progression from foundational research materials through clinical to commercial manufacturing.

Product and service7 records
1CDMO Solutions
CategoryContract Development and Manufacturing
Description

End-to-end Contract Development and Manufacturing Organization services for cell and gene therapy developers, spanning from cellular starting materials through plasmid DNA, viral vector production, and cell therapy manufacturing with industry-leading timelines. Targets advanced therapy developers from early-stage research through commercial supply.

2Plasmid DNA Manufacturing Services
CategoryBiological Starting Material Manufacturing
Description

Fit-for-purpose plasmid production from research to High Quality and GMP grades using the eXpDNA™ platform, supporting all stages of clinical development through commercial supply. Delivers HQ plasmid in as little as 5 weeks and GMP plasmid in 10 weeks from the Keele, UK facility. Serves gene therapy and mRNA developers requiring critical starting materials.

3Viral Vector Manufacturing Services
CategoryViral Vector Contract Manufacturing
Description

GMP manufacturing of AAV, lentiviral, adenovirus, and retrovirus vectors using the proprietary nAAVigation® and Lentivation™ platforms, reducing production timelines by up to 60% compared to traditional workflows. Serves gene therapy developers requiring reliable viral vector supply for clinical and commercial programs.

4Cell Therapy CDMO Services
CategoryCell Therapy Contract Manufacturing
Description

End-to-end cell therapy manufacturing including process development, analytical development, MSAT functions, and GMP manufacturing for autologous and allogeneic cell therapies across 30+ cell types (CAR-T, NK cells, TILs, MSCs). Operates from 25 dedicated GMP suites in Memphis, TN and supports clinical-to-commercial scale transitions.

5Cell Solutions
CategoryCellular Starting Materials Supply
Description

Cell sourcing capabilities providing human immune cells, stem cells, and GMP-compliant cellular starting materials including leukopaks, PBMCs, bone marrow aspirate, cord blood, iPSCs, and disease-state biospecimens. Built on 45+ years of supplying human cells with a diverse and recallable donor pool, backed by FDA 21 CFR Part 1271, AABB, and CLIA compliance.

6Off-the-Shelf Plasmid Products
CategoryResearch-Grade Plasmid Products
Description

Premium portfolio of pre-manufactured plasmid products designed for commonly used sequences and configurations to enhance and streamline gene therapy research and discovery programs. Available for immediate purchase by research-stage developers.

7Viral Vector Packaging Services
CategoryViral Vector Research Services
Description

Customizable AAV packaging at multiple scales for every phase of research, and custom lentiviral packaging for HQ and GMP grades. Targets gene therapy researchers and developers requiring vector production without full CDMO program commitment.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Ongoing long-term commercial partnership between Rose BioSolutions and Charles River provides continued access to clinical testing capabilities. Rose BioSolutions maintains regulatory history, qualifications, and relationships from its Charles River heritage while operating independently.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Specialized viral vector and cell therapy CDMO focused on early-stage gene therapy developers; competes with Rose's Rockville viral vector and Memphis cell therapy offerings at the clinical stage.

TypeDirect peer
Description

Global CDMO with the largest cell and gene therapy manufacturing footprint, offering viral vector and cell therapy services that directly compete with Rose BioSolutions across modalities and customer segments.

TypeEmerging player
Description

Emerging cell therapy manufacturing automation company offering integrated cell therapy production platforms; comparable cell therapy focus but differentiated by automation-first model.

4Vineti (now part of Dawako) / TrakCel
TypeOthers
Description

Cell therapy orchestration and chain-of-custody software providers; adjacent ecosystem players supporting the same autologous cell therapy manufacturing workflows Rose serves.

TypeDirect peer
Description

Major cell and gene therapy CDMO with commercial-scale viral vector and cell therapy capabilities, now owned by Novo Holdings; competes head-to-head with Rose for advanced therapy contracts.

TypeBroad incumbent
Description

Diversified life sciences giant with viral vector and cell therapy capabilities embedded in its pharma services segment; competes for biotech CDMO contracts at scale.

TypeDirect peer
Description

Specialized plasmid DNA and viral vector manufacturer serving gene therapy developers; most directly comparable to Rose's Keele plasmid and Rockville viral vector operations.

TypeDirect peer
Description

Cell and gene therapy CDMO with viral vector and cell therapy manufacturing across multiple sites; comparable service portfolio targeting similar advanced therapy clients.

TypeDirect peer
Description

Provides plasmid, viral vector, and cell therapy CDMO services globally with a comparable integrated continuum; competes directly with Rose on price, scale, and timeline.

TypeBroad incumbent
Description

Large-scale biologics CDMO expanding into cell and gene therapy; broader portfolio with massive scale that competes for the largest commercial-stage programs Rose also targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rose BioSolutions

Cell and Gene Therapy CDMO Servicesrosebiosolutions.com

Rose BioSolutions is a privately held CDMO providing cell and gene therapy developers with GMP plasmid, viral-vector, cellular starting-material manufacturing, and related development services across U.S. and U.K. facilities through project-based contracts.

What Rose BioSolutions does

Rose BioSolutions is a privately held, PE-backed contract development and manufacturing organization focused on cell and gene therapy. It was formed in May 2026 when GI Partners acquired Charles River Laboratories' CDMO and Cell Solutions businesses. Headquartered in Memphis, Tennessee, Rose operates facilities in Memphis and Rockville, Maryland, and Keele, United Kingdom, with an indicated workforce of roughly 500 employees and 25 GMP suites.

Its service portfolio includes GMP plasmid manufacturing through eXpDNA, AAV vector production through nAAVigation, lentiviral vectors through Lentivation, cellular starting materials through Cell Solutions, and broader cell therapy CDMO services. Rose reports more than 30 years of viral-vector experience, more than 20 years of GMP manufacturing experience, regulatory approvals associated with the FDA, EMA, and MHRA, and 200 GMP-compliant products.

Rose serves more than 35 cell therapy clients. Named examples include AAVantgarde, a small biotechnology company, and the FOXG1 Research Foundation, a nonprofit organization. The business uses quote-based, project-based contracting, and the company is positioned to continue investing in infrastructure, capacity, and technical capabilities while a Charles River partnership for clinical testing continues.

Rose BioSolutions firmographics

Firmographics
Name
Rose BioSolutions
Legal name
Rose BioSolutions
Website
https://rosebiosolutions.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
251–500 employees
Short description
Rose BioSolutions is a privately held CDMO providing cell and gene therapy developers with GMP plasmid, viral-vector, cellular starting-material manufacturing, and related development services across U.S. and U.K. facilities through project-based contracts.
Ownership category
akta.pro rank

Rose BioSolutions industry classification

Industry
Product category
Cell and Gene Therapy CDMO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cell therapy manufacturing
  • Gene therapy CDMO
  • Plasmid DNA production
  • Viral vector manufacturing
  • Biologics contract development

Where Rose BioSolutions is headquartered

Location

Headquarters

HQ city
Memphis
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Rose BioSolutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. CDMO Manufacturing Services: Contract Development and Manufacturing Organization services including plasmid DNA manufacturing, viral vector manufacturing, and cell therapy manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies developing advanced therapies.
  2. Cell and Biospecimen Products: Sale of human immune cells, stem cells, leukopaks, GMP-compliant cellular starting materials, and related biological products for research and clinical use.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom CDMO service quotes based on project scope, phase, and grade requirements

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Rose BioSolutions product offering

Product offering

Core offering

Rose BioSolutions is a Contract Development and Manufacturing Organization (CDMO) providing integrated cell and gene therapy manufacturing services across plasmid DNA, viral vectors, and cell therapy production. The company also supplies cellular starting materials (human immune cells, stem cells, leukopaks, and GMP-compliant biological products) for advanced therapy developers. Services span research-grade through GMP-grade production and include process development, analytical development, and regulatory support.

Product overview

Rose BioSolutions offers an integrated portfolio of advanced therapy manufacturing services and cellular starting materials. The core offering centers on CDMO Solutions providing end-to-end Contract Development and Manufacturing Organization services across plasmid DNA manufacturing (via the eXpDNA platform), viral vector manufacturing (via nAAVigation and Lentivation platforms), and cell therapy CDMO services. Complementing these are Cell Solutions for sourcing human immune cells, stem cells, and GMP-compliant cellular starting materials. The company also provides specialized sub-products including off-the-shelf plasmid products, viral vector packaging services, CAR-T manufacturing support, and quality/regulatory services. This unified portfolio enables seamless progression from foundational research materials through clinical to commercial manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • nAAVigation®: Proprietary adeno-associated viral (AAV) vector production platform that reduces production timelines by over 60%
  • Lentivation™
  • eXpDNA™

Products and services

  • CDMO Solutions End-to-end Contract Development and Manufacturing Organization services for cell and gene therapy developers, spanning from cellular starting materials through plasmid DNA, viral vector production, and cell therapy manufacturing with industry-leading timelines. Targets advanced therapy developers from early-stage research through commercial supply.
  • Plasmid DNA Manufacturing Services Fit-for-purpose plasmid production from research to High Quality and GMP grades using the eXpDNA™ platform, supporting all stages of clinical development through commercial supply. Delivers HQ plasmid in as little as 5 weeks and GMP plasmid in 10 weeks from the Keele, UK facility. Serves gene therapy and mRNA developers requiring critical starting materials.
  • Viral Vector Manufacturing Services GMP manufacturing of AAV, lentiviral, adenovirus, and retrovirus vectors using the proprietary nAAVigation® and Lentivation™ platforms, reducing production timelines by up to 60% compared to traditional workflows. Serves gene therapy developers requiring reliable viral vector supply for clinical and commercial programs.
  • Cell Therapy CDMO Services End-to-end cell therapy manufacturing including process development, analytical development, MSAT functions, and GMP manufacturing for autologous and allogeneic cell therapies across 30+ cell types (CAR-T, NK cells, TILs, MSCs). Operates from 25 dedicated GMP suites in Memphis, TN and supports clinical-to-commercial scale transitions.
  • Cell Solutions Cell sourcing capabilities providing human immune cells, stem cells, and GMP-compliant cellular starting materials including leukopaks, PBMCs, bone marrow aspirate, cord blood, iPSCs, and disease-state biospecimens. Built on 45+ years of supplying human cells with a diverse and recallable donor pool, backed by FDA 21 CFR Part 1271, AABB, and CLIA compliance.
  • Off-the-Shelf Plasmid Products Premium portfolio of pre-manufactured plasmid products designed for commonly used sequences and configurations to enhance and streamline gene therapy research and discovery programs. Available for immediate purchase by research-stage developers.
  • Viral Vector Packaging Services Customizable AAV packaging at multiple scales for every phase of research, and custom lentiviral packaging for HQ and GMP grades. Targets gene therapy researchers and developers requiring vector production without full CDMO program commitment.

Quantifiable outcome

  • Up to 60% reduction in viral vector production timelines using proprietary platforms
  • +5 more outcomes

Companies that use Rose BioSolutions

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Rose BioSolutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Rose BioSolutions partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Charles River LaboratoriesmajorStrategic or Co-development Partner · 1 May 2026Ongoing long-term commercial partnership between Rose BioSolutions and Charles River provides continued access to clinical testing capabilities. Rose BioSolutions maintains regulatory history, qualifications, and relationships from its Charles River heritage while operating independently.

Scale indicators9 records

Recent moves2 records

Expansion highlights4 records

Rose BioSolutions competitors and assessment

Company assessment

Emerging players

  • Genezen: Specialized viral vector and cell therapy CDMO focused on early-stage gene therapy developers; competes with Rose's Rockville viral vector and Memphis cell therapy offerings at the clinical stage.
  • Cellares: Emerging cell therapy manufacturing automation company offering integrated cell therapy production platforms; comparable cell therapy focus but differentiated by automation-first model.

Direct peers

  • Lonza Cell & Gene Technologies: Global CDMO with the largest cell and gene therapy manufacturing footprint, offering viral vector and cell therapy services that directly compete with Rose BioSolutions across modalities and customer segments.
  • Catalent (Novo Holdings): Major cell and gene therapy CDMO with commercial-scale viral vector and cell therapy capabilities, now owned by Novo Holdings; competes head-to-head with Rose for advanced therapy contracts.
  • Aldevron (Danaher): Specialized plasmid DNA and viral vector manufacturer serving gene therapy developers; most directly comparable to Rose's Keele plasmid and Rockville viral vector operations.
  • AGC Biologics: Cell and gene therapy CDMO with viral vector and cell therapy manufacturing across multiple sites; comparable service portfolio targeting similar advanced therapy clients.
  • WuXi Advanced Therapies Unit (WuXi AppTec): Provides plasmid, viral vector, and cell therapy CDMO services globally with a comparable integrated continuum; competes directly with Rose on price, scale, and timeline.

Others

  • Vineti (now part of Dawako) / TrakCel: Cell therapy orchestration and chain-of-custody software providers; adjacent ecosystem players supporting the same autologous cell therapy manufacturing workflows Rose serves.

Broad incumbents

  • Thermo Fisher Scientific (Patheon/Pharma Services): Diversified life sciences giant with viral vector and cell therapy capabilities embedded in its pharma services segment; competes for biotech CDMO contracts at scale.
  • Samsung Biologics: Large-scale biologics CDMO expanding into cell and gene therapy; broader portfolio with massive scale that competes for the largest commercial-stage programs Rose also targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks3 records

Key highlights7 records

Customer concentration

Rose BioSolutions social profiles

Digital presence

Rose BioSolutions compliance and trust

Trust signal

Compliance8 records

Rose BioSolutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rose BioSolutions leadership team

Management profile

Number of profiles

Rose BioSolutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rose BioSolutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rose BioSolutions

What does Rose BioSolutions do?

Rose BioSolutions is a Contract Development and Manufacturing Organization (CDMO) providing integrated cell and gene therapy manufacturing services across plasmid DNA, viral vectors, and cell therapy production. The company also supplies cellular starting materials (human immune cells, stem cells, leukopaks, and GMP-compliant biological products) for advanced therapy developers. Services span research-grade through GMP-grade production and include process development, analytical development, and regulatory support.

Is Rose BioSolutions a public or private company?

Rose BioSolutions is a private company. It is classified as private equity controlled and is currently operating.

When was Rose BioSolutions founded?

Rose BioSolutions was founded in 2026. It employs 251 to 500 people.

Where is Rose BioSolutions based?

Rose BioSolutions is headquartered in Memphis, United States, in the North America region.

How does Rose BioSolutions make money?

Two revenue lines are on record. CDMO Manufacturing Services are the primary driver. The others are cell and Biospecimen Products.

Who are Rose BioSolutions's main competitors?

Emerging players on record are Genezen and Cellares. Direct peers are Lonza Cell & Gene Technologies, Catalent (Novo Holdings), Aldevron (Danaher), AGC Biologics and WuXi Advanced Therapies Unit (WuXi AppTec). Vineti (now part of Dawako) / TrakCel is listed as an others. Broad incumbents are Thermo Fisher Scientific (Patheon/Pharma Services) and Samsung Biologics.

Does Rose BioSolutions have an API?

No public API is recorded for Rose BioSolutions.

What industry is Rose BioSolutions in?

Rose BioSolutions's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsBeyond Outsourcing: Building Better CDMO PartnershipsDavid Enloe, CEO of Rose BioSolutions, argues that advanced therapies require CDMOs to act as extensions of sponsors' teams, not just vendors. He emphasizes early risk identification and shared accountability to avoid costly rework. The model aims to improve patient outcomes by integrating development and manufacturing.GenengnewsDecentralization, AI, and Gene Editing Are Opportunities for CGT ContractorsDecentralization, AI, and gene editing are expanding CGT production opportunities for third-party contractors, with 66-90% of CGT production outsourced. Rose Biosolutions executives say CDMOs can support decentralized manufacturing and that new gene editing strategies will impact the industry.BioSpaceSuccessful CDMO partnerships hinge on honest—and sometimes critical—supportCDMO-sponsor relationships have shifted from transactional outsourcing to strategic collaboration, with partners like Rose BioSolutions emphasizing shared risk and regulatory fluency. The article notes rising FDA inspections in 2025 and argues CDMOs should anticipate hurdles and challenge sponsor assumptions. It stresses that product definition and regulatory strategy at program outset are key to success.PR NewswireRose BioSolutions Appoints David Enloe as Chief Executive OfficerRose BioSolutions appointed David Enloe as CEO, bringing over 35 years of biotech and pharma services experience. He previously led Introgen Therapeutics, founded Vivante GMP Solutions, and served as CEO of Societal CDMO and Ajinomoto Bio-Pharma Services. He aims to advance Rose Bio's end-to-end platform for cell and gene therapies.citybizRose BioSolutions Names Thomas VanCott to Lead HemaCare Cell SolutionsRose BioSolutions appointed Thomas VanCott, Ph.D., as head of HemaCare, its Cell Solutions business, tasked with overseeing cellular material sourcing and related services for cell and gene therapy developers. VanCott previously served as CEO of Excellos, a cell therapy CDMO, and brings over 30 years of experience. The Cell Solutions business will rebrand as HemaCare, following Rose Bio's independence earlier this year.PR NewswireRose BioSolutions Appoints Thomas VanCott, Ph.D., as Head of HemaCareRose BioSolutions appointed Thomas VanCott, Ph.D., as Head of HemaCare, its Cell Solutions business. He previously served as CEO of Excellos, a cell therapy CDMO. The Cell Solutions business will rebrand as HemaCare, following Rose Bio's formation from GI Partners' acquisition of Charles River's CDMO and Cell Solutions businesses.GenengnewsEmbedding Regulatory Strategy in Cell and Gene Therapy DevelopmentRose BioSolutions is hosting a webinar on September 17, 2026, to discuss embedding regulatory strategy into cell and gene therapy development. The session will feature experts Jeffrey Mocny and Felicia Irons, who will outline how early integration of regulatory planning reduces risk and improves program outcomes. Attendees will learn practical approaches for aligning development activities with product-specific requirements and compliance expectations.BioSpaceGI Partners Completes Acquisition of the CDMO and Cell Solutions Businesses from Charles River Laboratories and forms Rose BioSolutionsGI Partners has completed the acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories International, forming Rose BioSolutions as an independent company focused on cell and gene therapy manufacturing. The new entity brings together plasmid DNA, viral vector, and cell therapy capabilities alongside cellular materials supply, positioning itself as an end-to-end partner for advanced therapy development. With backing from GI Partners and facilities across the US and UK, Rose Bio aims to invest in infrastructure and accelerate innovation in the growing advanced therapy sector.PR NewswireGI Partners Completes Acquisition of the CDMO and Cell Solutions Businesses from Charles River Laboratories and forms Rose BioSolutionsGI Partners has completed the acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories International, forming a new independent company called Rose BioSolutions. Rose BioSolutions is positioned as a leading provider of advanced manufacturing capabilities in the cell and gene therapy space, offering end-to-end services including plasmid DNA, viral vector, and cell therapy manufacturing. The new company will operate facilities across multiple U.S. locations and the United Kingdom, with backing from GI Partners to drive innovation and growth in the advanced therapy sector.